# US 11,440,930 B2 · Preparation method of high-purity total ginkgo flavonol glycoside and application of same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,440,930 B2
- Document ID: US11440930B2
- Status: Granted
- Kind: B2
- Application number: 16/956,612
- Filed: 2018-04-10
- Published: 2021-02-25
- Granted: 2022-09-13
- Earliest claimed: 2017-12-20
- Assignees: SPH Xing Ling Sci. & Tech. Pharmaceutical Co., Ltd.
- Applicants: SPH Xing Ling Sci. & Tech. Pharmaceutical Co., Ltd.
- Inventors: Shuang Liang; Xiangwei Zheng; Qi Gao; Dandan Wang; Guoqin Zhu
- Web page: https://patentgrep.com/patent/US11440930B2

## CPC

- C07H 1/08: from natural products
- A61K 31/7084: Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
- A61K 36/16: Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/04: Immunostimulants
- C07H 17/04: Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to the field of pharmacology, and in particular, to a preparation method of high-purity total ginkgo flavonol glycoside. The preparation method of high-purity total ginkgo flavonol glycoside includes: (1) mixing Ginkgo biloba extract powder and a first alkaline solution, subjecting to dissolution and centrifugation to obtain a supernatant; (2) subjecting the supernatant to separation with an acid-polar coupled macroporous resin column and to purification with a polyamide column, to obtain high-purity total ginkgo flavonol glycoside. The purity of the total ginkgo flavonol glycoside prepared by the preparation method of high-purity total ginkgo flavonol glycoside according to the present disclosure is ≥90%, and has good clinical application prospects; the preparation process does not require organic reagents such as petroleum ether and ethyl acetate, which is environmentally friendly; the transfer rate of the total flavonol glycoside is high.

## Claims

### Claim 1

A method for preparing a total ginkgo flavonol glycoside, comprising the following operations:
(1) mixing Ginkgo biloba extract powder with a first alkaline solution, subjecting to dissolution and centrifugation to obtain a supernatant;
(2) subjecting the supernatant to separation and purification by an acid-polar coupled macroporous resin column and a polyamide column, to obtain a high-purity total ginkgo flavonol glycoside; wherein
a diameter-height ratio of the acid-polar coupled macroporous resin column is 1:5˜1:9; and
an absorbtion ratio of the acid-polar coupled macroporous resin column is 1:30˜1:50.

### Claim 2 (depends on 1)

The preparation method according to claim 1, wherein the dissolution in operation (1) is an ultrasonic treatment, and an ultrasonic time is 30˜60 minutes.

### Claim 3 (depends on 1)

The preparation method according to claim 1, wherein the first alkaline solution is a Na2CO3 aqueous solution with a mass fraction of 0.1˜0.4%.

### Claim 4 (depends on 1)

The preparation method according to claim 1, wherein operation (2) comprises: loading the supernatant onto the acid-polar coupled macroporous resin column, and eluting with a second alkaline solution to obtain an eluent; drying the eluent to obtain a solid substance; dissolving the solid substance to obtain an acidic solution; loading the acidic solution onto the polyamide column, eluting with an aqueous ethanol solution, and drying to obtain the total ginkgo flavonol glycoside.

### Claim 5 (depends on 4)

The preparation method according to claim 4, wherein the second alkaline solution is a Na2CO3 aqueous solution with a mass fraction of 0.1˜0.3%.

### Claim 6 (depends on 4)

The preparation method according to claim 4, wherein a pH value of the acidic solution is 1˜3.

### Claim 7 (depends on 1)

The preparation method according to claim 1, wherein operation (1) comprises mixing every 1 g of Ginkgo biloba extract powder with every 20˜50 ml of the first alkaline solution.